• 1
    Rosen J, Bohon S, Gershon S. Antipsychotics in elderly. Acta Psychiatr Scand 1990; 358: 170175.
  • 2
    Boettger S, Breutbart W. Atypical antipsychotics in the management of delirium: A review of the empirical literature. Palliat Support Care 2005; 3: 227237.
  • 3
    Sipahimalani A, Sime RM, Masand PS. Treatment of delirium with risperidone. Int J Geriatr Psychopharmacol 1997; 1: 2426.
  • 4
    Horikawa N, Yamazaki T, Miyamoto K et al. Treatment for delirium with risperidone: Results of a prospective open trial with 10 patients. Gen Hosp Psychiatry 2003; 25: 289292.
  • 5
    Parellada E, Baeza I, De Pablo J et al. Risperidone in the treatment of patients with delirium. J Clin Psychiatry 2004; 65: 348353.
  • 6
    American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999; 156: 120.
  • 7
    Jacobi J, Fraser GL, Coursin DB. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adults. Crit Care Med 2002; 30: 119141.
  • 8
    Cruzan S. FDA Issues Public Health Advisory for Antipsychotic Drugs Used for Treatment of Behavioral Disorders in Elderly Patients. Available online at[accessed 10 June 2006].
  • 9
    Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353: 23352341.
  • 10
    Ryan CJ. Optimizing management of delirium: Placebo controlled trials of pharmacological treatments are needed. BMJ 2001; 322: 144149.
  • 11
    Kato T, Hirose A, Ohno Y et al. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 1990; 54: 478481.
  • 12
    De Paulis T. Perospirone. Curr Opin Invest Drugs 2002; 3: 121129.
  • 13
    Hirose A, Kato T, Ohono Y et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990; 53: 321329.
  • 14
    Yasui-Furukori N, Furukori H, Nakagami T et al. Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 2004; 26: 361365.
  • 15
    Sato S, Mizukami K, Moro K et al. Efficacy of perospirone in the management of aggressive behavior associated with dementia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 679683.
  • 16
    Ito Y. Clinical effects of perospirone on delirium with senile dementia at nursing home care. Jpn J Clin Psychopharmacol 2004; 7: 981990.
  • 17
    Komori K, Komori M, Maekawa K, Kanemoto K. A prospective, open-label, flexible-dose study of perospirone in the treatment of delirium. Jpn J Clin Psychopharmacol 2004; 8: 14491454.
  • 18
    Trzepacz PT, Baker RW, Greenhouse J. A symptom ratining scale for delirium. Psychiatry Res 1988; 23: 8997.
  • 19
    Trzepacz PT. The Delirium Rating Scale. Its use in consultation–liaison research. Psychosomatics 1999; 40: 193204.
  • 20
    World Health Organization. International Classification of Diseases and Related Health Problems, 10th revision. Geneva: World Health Organization, 1992.
  • 21
    Takahashi Y, Kusumi I, Shikane T et al. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 1998; 105: 181191.